Wednesday, October, 16, 2019 08:04:56

Category: Pharmaceuticals

Fulcrum bags global rights for GSK’s failed trial drug Losmapimod

Fulcrum plans to initiate a Phase 2b clinical trial in mid-2019 on patients with FSHD in the U.S. and Europe. Fulcrum Therapeutics, a biotechnology firm focused on discovering and developing therapies to rebalance gene expression, has recently announced its exclusive global license agreement with British …

Alembic Pharma receives FDA approval for Teriflunomide tablets

The company now possesses over 91 ANDA approvals, approximately 79 final approvals & 12 tentative approvals, from the FDA. Company shares went up by 1% following the FDA approval of the Teriflunomide tablets. Alembic Pharmaceuticals Ltd (Alembic), a renowned Indian multinational pharmaceutical company, has reportedly …

Roche Pharma introduces Hemophilia A treatment drug in India

The new drug would be sold under the brand name Hemlibra in the country It represents an entirely new way to manage Hemophilia A and reviews the standard of care Roche Pharmaceuticals, the Swiss multinational healthcare company, has reportedly announced that it has introduced Emicizumab …

Dr. Reddy’s Laboratories acquires 42 ANDAs portfolio in the U.S.

The portfolio in question includes over 30 generic injectable products.  The latest acquisition expands Dr. Reddy’s current portfolio by a considerable margin. Dr. Reddy’s Laboratories Ltd., (Dr. Reddy’s), a renowned Indian multinational pharmaceutical firm based out of Hyderabad, has reportedly entered into a definitive agreement …

GlaxoSmithKline Plc receives U.S FDA approval for HIV drug Dovato

One of the world’s leading pharma company GlaxoSmithKline Plc has reportedly attained the approval of the U.S. FDA for marketing its two-drug treatment for HIV infections, thereby boosting its growth prospects against rival Gilead Sciences Inc. As per trusted sources, the U.S. FDA cleared Dovato, …

Aeglea presents positive data for Pegzilarginase to treat ARG1-D

The clinical-stage biotechnology company, Aeglea BioTherapeutics Inc., has reportedly announced positive Phase 1/2 data for Pegzilarginase to be used in the treatment of patients with ARG1-D (Arginase 1 Deficiency). Dr. George Diaz, Ph.D., M.D., Division Chief of Medical Genetics, Icahn School of Medicine, New York, …

Viking Therapeutics to present data from Phase 2 study of VK2809

Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. will reportedly present data from its 12-week long Phase 2 trial of VK2809 on individuals suffering from non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol at the International Liver Congress™ 2019. According to familiar sources, the study results …